劲方医药-B今日盘中大跌5.28%，引起了市场的广泛关注。
消息面上，公司此前发布公告，澄清Revolution Medicines Inc.向第三方公司发出的有关RAS抑制剂专利及商业秘密争议的函件，所涉主体、产品及争议事项均与公司无关。公司强调，其旗下Pan RAS抑制剂GFH276具备完全独立、自主原创的知识产权，相关专利保护期预计可至2044年，不存在类似侵权风险。然而，尽管公司已发布澄清声明，市场情绪仍未完全消化，导致股价延续前一交易日的跌势。
此次股价波动凸显了市场对生物科技公司知识产权状况的高度敏感，即使在公司主动澄清后，投资者信心仍需时间恢复。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.